Day & Ennis LLC trimmed its stake in AbbVie Inc (NYSE:ABBV) by 29.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,334 shares of the company’s stock after selling 3,114 shares during the period. Day & Ennis LLC’s holdings in AbbVie were worth $652,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of ABBV. Hudock Capital Group LLC lifted its stake in shares of AbbVie by 109.5% during the 2nd quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock worth $111,000 after acquiring an additional 806 shares during the last quarter. Ffcm LLC lifted its stake in shares of AbbVie by 167.2% during the 2nd quarter. Ffcm LLC now owns 1,539 shares of the company’s stock worth $111,000 after acquiring an additional 963 shares during the last quarter. Bristlecone Advisors LLC bought a new stake in shares of AbbVie during the 3rd quarter worth approximately $113,000. BDO Wealth Advisors LLC bought a new stake in shares of AbbVie during the 2nd quarter worth approximately $115,000. Finally, Hershey Trust Co. purchased a new position in AbbVie during the 3rd quarter worth $139,000. 69.33% of the stock is owned by institutional investors and hedge funds.

In other news, Chairman Richard A. Gonzalez sold 218,193 shares of AbbVie stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $94.01, for a total value of $20,512,323.93. Following the transaction, the chairman now directly owns 492,030 shares in the company, valued at approximately $46,255,740.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Timothy J. Richmond sold 87,040 shares of AbbVie stock in a transaction on Monday, December 18th. The shares were sold at an average price of $98.45, for a total value of $8,569,088.00. Following the completion of the transaction, the senior vice president now owns 113,118 shares in the company, valued at $11,136,467.10. The disclosure for this sale can be found here. Insiders sold a total of 450,743 shares of company stock worth $43,153,684 over the last quarter. Company insiders own 0.23% of the company’s stock.

ABBV has been the topic of several research reports. Jefferies Group raised their price objective on AbbVie from $107.00 to $115.00 and gave the stock a “buy” rating in a report on Monday, October 16th. BMO Capital Markets set a $66.00 price objective on AbbVie and gave the stock a “hold” rating in a report on Friday, October 27th. BidaskClub upgraded AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 11th. Piper Jaffray Companies raised their price objective on AbbVie to $115.00 and gave the stock an “overweight” rating in a report on Friday, October 27th. Finally, SunTrust Banks restated a “buy” rating on shares of AbbVie in a report on Monday, October 30th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $117.26.

AbbVie Inc (NYSE ABBV) opened at $111.93 on Tuesday. AbbVie Inc has a fifty-two week low of $60.15 and a fifty-two week high of $125.86. The stock has a market capitalization of $177,682.66, a price-to-earnings ratio of 19.91, a PEG ratio of 1.06 and a beta of 1.60. The company has a debt-to-equity ratio of 5.08, a current ratio of 1.45 and a quick ratio of 1.32.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, January 26th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.44 by $0.04. AbbVie had a return on equity of 152.78% and a net margin of 18.82%. The business had revenue of $7.74 billion for the quarter, compared to the consensus estimate of $7.53 billion. During the same period last year, the business posted $1.20 EPS. The business’s revenue was up 13.9% compared to the same quarter last year. sell-side analysts anticipate that AbbVie Inc will post 7.46 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://theolympiareport.com/2018/02/13/day-ennis-llc-has-652000-stake-in-abbvie-inc-abbv.html.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.